Anjali S Advani
SWOG Network Cancer Center · SWOG Cancer Research Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anjali S Advani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06773936 · Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaSWOG Cancer Research Network · enrolling by invitation · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia · principal investigator
- Ph1/Ph2NCT04315324 · Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)SWOG Cancer Research Network · active not recruiting · Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma · principal investigator
- Ph2NCT02143414 · Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI) · active not recruiting · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT04315324, NCT02143414
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:35 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- 1,127 citationsRCR 36.3
- 429 citationsRCR 16.8
- 298 citationsRCR 11.8
- 281 citationsRCR 14.8
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.N Engl J Med · 2024258 citationsRCR 31.2
- Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.Lancet Haematol · 2017189 citationsRCR 6.5
- Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.Clin Cancer Res · 2021187 citationsRCR 9.1
- 160 citationsRCR 5.3
- 114 citationsRCR 3.0
- 102 citationsRCR 6.4